Azithromycin (ophthalmic) indications and usage: Difference between revisions

Latest revision as of 21:41, 5 January 2014

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]

AzaSite® is indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following microorganisms:

Efficacy for this organism was studied in fewer than 10 infections.^[1]

Adapted from the FDA Package Insert.

@@ Line 1: / Line 1: @@
 __NOTOC__
-{{Azithromycin}}
+{{Azithromycin (ophthalmic)}}
-{{CMG}}
+{{CMG}}; {{AE}} {{SS}}
 ==Indications And Usage==
 AzaSite® is indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following microorganisms:
-CDC coryneform group G1
+* CDC coryneform group G1
+* [[Haemophilus influenzae]]
-[[Haemophilus influenzae ]]
+* [[Staphylococcus aureus]]
-[[Staphylococcus aureus]]
+* [[Streptococcus mitis]] group
-[[Streptococcus]] mitis group
+* [[Streptococcus pneumoniae]]
-[[Streptococcus pneumoniae]]
-<sup>1</sup>Efficacy for this organism was studied in fewer than 10 infections.<ref>{{Cite web | last = | first =|title = http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050710s039,050711s036,050784s023lbl.pdf | url =http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050710s039,050711s036,050784s023lbl.pdf | publisher = |date = | accessdate = }}</ref>
+Efficacy for this organism was studied in fewer than 10 infections.<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  |title = AZASITE (AZITHROMYCIN) SOLUTION [INSPIRE PHARMACEUTICALS, INC.] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5dc0f75a-1e14-469f-af4f-c668a32f2328 |publisher =  | date =  | accessdate = }}</ref>
 ==References==